Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial
Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The aim of this randomized, doube-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patint with post-COVID who experience post-exertional malaise (PEM).
Phase:
PHASE2
Details
Lead Sponsor:
Michele van Vugt
Collaborators:
Khondrion BV ZonMw: The Netherlands Organisation for Health Research and Development